Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - valsartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 80mg+12,5mg 90tk; 80mg+12,5mg 28tk; 80mg+12,5mg 98tk; 80mg+12,5mg 20tk; 80mg+12,5mg 280tk; 80mg+12,5mg 30tk; 80mg+12,5mg 100tk; 80mg+12,5mg 15tk; 80mg+12,5mg 56tk; 80mg+12,5mg 7tk; 80mg+12,5mg 10tk; 80mg+12,5mg 50tk; 80mg+12,5mg 60tk

Eesti - eesti - Ravimiamet

recordati ireland limited - enalapriil+lerkanidipiin - õhukese polümeerikattega tablett - 10mg+10mg 56tk; 10mg+10mg 90tk; 10mg+10mg 42tk; 10mg+10mg 50tk; 10mg+10mg 7tk; 10mg+10mg 30tk; 10mg+10mg 100tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - okskarbasepiin - õhukese polümeerikattega tablett - 150mg 100tk; 150mg 50tk; 150mg 56tk; 150mg 200tk; 150mg 500tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 20mg+5mg 14tk; 20mg+5mg 56tk; 20mg+5mg 100tk; 20mg+5mg 10tk; 20mg+5mg 28tk; 20mg+5mg 98tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - dabigatraaneteksilaat - kõvakapsel - 110mg 60tk; 110mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - imatiniib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatiniib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. välja arvatud äsja diagnoositud kroonilise faasi cml, ei ole kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused. .

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - etorikoksiib - õhukese polümeerikattega tablett - 90mg 30tk; 90mg 84tk; 90mg 98tk; 90mg 50tk; 90mg 90tk; 90mg 100tk; 90mg 20tk; 90mg 14tk; 90mg 5tk; 90mg 28tk; 90mg 10tk

Eesti - eesti - Ravimiamet

aurobindo pharma limited - simvastatiin - õhukese polümeerikattega tablett - 10mg 28tk; 10mg 90tk; 10mg 60tk; 10mg 84tk; 10mg 14tk; 10mg 20tk; 10mg 98tk; 10mg 56tk; 10mg 10tk

Eesti - eesti - Ravimiamet

teva b.v. - atsitretiin - kõvakapsel - 10mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuuria, paroksüsmaalne - selektiivsed immunosupressandid - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.